What You Should Know
- As new options like daraxonrasib (Rasonque) emerge for metastatic pancreatic cancer, meaning cancer that has spread, staying strong enough to receive them has become critical.
- In a key trial, patients on daraxonrasib lived a median of 13.2 months, versus 6.7 months on chemotherapy, but the study enrolled only patients who were still active and able to care for themselves.
- Dr. Karyn Goodman of Mount Sinai says pancreatic cancer often causes pain, jaundice (yellowing of the skin and eyes), poor appetite and weight loss, which can leave patients too weak for their next treatment or a clinical trial.
- Social workers, nutritionists and supportive oncology specialists work together to manage symptoms and keep patients healthy enough for current and future therapies.
Daraxonrasib is the first approved targeted therapy in pancreatic cancer designed to inhibit RAS, a protein that acts as the major cancer-driving pathway in the disease. In the RASolute 302 clinical trial, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with chemotherapy. Median means half the patients lived longer than that, and half lived for a shorter time.
Read More“They also sometimes have a lack of appetite. They’re losing weight. They have abdominal pain or back pain. All of these symptoms can be really challenging, and so we often get a whole group of physicians and other affiliated professionals involved.”
Social Work: Removing Barriers to Starting Treatment
At Mount Sinai, Dr. Goodman says, social workers are involved early.
“We often have our social workers involved to help make sure that patients have all of the things that they need at home, and that they have transportation to get to the hospital,” Dr. Goodman says.
“They can also help patients with the stress of getting through the diagnosis and being able to start the treatment plan.”
Supportive Oncology From the Start
Dr. Goodman’s team also brings in palliative care early, which her program calls supportive oncology. Palliative care focuses on relieving symptoms and improving quality of life, and it can be given at any stage of cancer, alongside treatment.
“We also have our palliative care, or we also call them supportive oncology physicians, who get involved and can help with providing pain medication and help with some of the side effects, like lack of appetite,” she says. “We can give medications to help with that.”
The American Society of Clinical Oncology’s 2024 guideline update recommends that oncology clinicians refer patients with advanced solid tumors to specialized interdisciplinary palliative care teams beginning early in the course of the disease, alongside active treatment. Unlike the earlier version, the 2024 update doesn’t set a specific time point from diagnosis.
Helpful Resources for Pancreatic Cancer Patients
- ‘A Watershed Moment’: Revolution Medicines Chief Development Officer Dr. Alan Sandler On The Breakthrough Giving New Hope in Pancreatic Cancer
- A Treatment That’s Changed the Conversation Around Pancreatic Cancer – ‘We Will Recommend This Pill…Rather Than Chemotherapy’
- For Advanced Pancreatic Cancer Patients Running Out of Treatments, a New Pathway Offers Renewed Hope Thanks to the FDA Granting ‘Compassionate Use’ Access to Daraxonrasib
- Pancreatic Cancer Treatment Just Became a Lot More Accessible; New Platform Is Designed to Test Multiple Therapies at the Same Time
Nutrition as a Treatment Enabler
“Oftentimes it’s a multi-step process for the treatment. So it’s also really important to include a nutritionist because so much of what we do … really is dependent on the patient being healthy enough to get their therapy,” Dr. Goodman says.
“And if they’re losing weight, that can be a real problem. So we are making sure they’re eating the right things, getting the right number of calories.”
Functional status isn’t only a quality-of-life measure. It also determines who can get the newest therapies. RASolute 302, for example, enrolled patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
ECOG performance status is a standard scale doctors use to measure how well a patient can carry out daily activities. The scale runs from 0 to 5:
- 0: Fully active, able to do everything they did before the illness.
- 1: Can’t do strenuous activity but is up and about, and can do light work like housework or office work.
- 2: Up and about more than half the day and able to care for themselves, but unable to work.
- 3: Able to do only limited self-care, and in bed or a chair more than half the day.
- 4: Completely disabled and confined to bed or a chair.
- 5: Death.
A patient who declines from weight loss and uncontrolled symptoms during first-line therapy, the first treatment given after diagnosis, may no longer be eligible for the next line, the treatment that comes after, or for a trial.
One Team, One Message
Dr. Goodman stresses that the treating physicians speak to patients together.
“Our surgeons, medical oncologist, radiation oncologist, each of us try to make sure we can explain everything in a way that the patient and their families understand, be able to talk about the side effects of the treatment, what to expect, understand what the prognosis is, and what the possibilities are for next steps after this.”
“So it’s a very comprehensive evaluation for our patients,” she adds. “We really are all a team working to help make the patient feel better and get through the treatment.”
Learn more about SurvivorNet's rigorous medical review process.
